Skip to Content

'
Richard E. Champlin, M.D.

Present Title & Affiliation

Primary Appointment

Chair, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor of Medicine, Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Division Head (ad interim), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor of Medicine, Division of Internal Medicine, The University of Texas Health Science Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
P.O. Box 301402
Unit Number: Unit 423
Houston, TX 77030
Room Number: Stem Cell Transplantation and Cellular Therapy - FC5.3042

Education & Training

Degree-Granting Education

1975 University of Chicago Pritzker School of Medicine, Chicago, IL, MD, Internal Medicine
1971 Purdue University, W. Lafayette, IN, BS, Engineering Sciences

Postgraduate Training

7/1978-1/1980 Fellowship, UCLA Center for the Health Sciences, Los Angeles, CA, Martin Cline, M.D.
7/1975-6/1978 Internship/Residency, UCLA School of Medicine, Los Angeles, CA, Williams ODell, M.D.

Board Certifications

1981 American Board of Internal Medicine, Med Oncology
1980 American Board of Internal Medicine, Hematology
1978 American Board of Internal Medicine, Internal Med

Experience/Service

Other Appointments/Responsibilities

Co-Chair, Graft Sources Committee, Center for International Blood and Marrow Transplantation Research, Minneapolis, MN, 2008-present
Member, Advisory Council on Blood Stem Cell Transplantation of U.S. Health Resources and Services Administration, Washington, DC, 2008-present
Chair, Center for International Blood and Marrow Transplantation Research, Minneapolis, MN, 2006-2007
Member, National Cancer Institute Parent Committee D, Bethesda, MD, 2003-2006
Chair, Autologous Bone Marrow Transplant Registry, Minneapolis, MN, 2003-2006
Member, U.S. Food and Drug Administration, Biologic Response Modifiers Advisory Committee, Silver Spring, MD, 1999-2002
Vice President, Foundation for the Accreditation of Cellular Therapy, Omaha, NE, 1996-2008
Member, Hematology Board, American Board of Internal Medicine, Philadelphia, PA, 1996-2002
President, American Society for Blood and Marrow Transplantation, Arlington Heights, IL, 1992-1994
President Council for Donor Collection and Transplant Centers and Board Member, National Donor Marrow Program, Minneapolis, MN, 1990-1994

Endowed Positions

Robert C. Hickey Chair of Clinical Cancer Care, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998

Institutional Committee Activities

Board Member, MD Anderson Physician Network, 9/2010-8/2013
Member, Revenue Cycle Advisory Committee, 2006-present
Member, MD Anderson Cancer Center Management Committee, 2006-2008
Member, Division of Cancer Medicine Advisory Committee, 2003-present
Co-Chair, Promotions and Tenure Committee, 2003-2004
Member, President's Advisory Board, 2001-present
Member, Clinical Council, 2001-2006
Member, Promotions and Tenure Committee, 2001-2003
Member, Clinical Faculty Review Committee, 2000-2003
Member, Division of Cancer Medicine Executive Committee, 1997-present
Member, Clinical Research Committee, 1994-1998
Member, Surveillance Committee (IRB),, 1992-2000

Honors and Awards

2011 2011 ASBMT Lifetime Achievement Award, American Society for Blood and Marrow Transplantation
2010 John Mendelsohn Lifetime Scientific Achievement Award, MD Anderson Cancer Center, Division of Cancer Medicine
2008 Waun Ki Hong Award for Excellence in Team Science, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine
1998 Robert C. Hickey Chair in Clinical Cancer Care, The University of Texas MD Anderson Cancer Center
1982-1984 National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases
1982-1984 New Investigator Research Award
1979-1981 Giannini Foundation Fellowship
1975 Alpha Omega Alpha, University of Chicago Pritzker School of Medicine
1968 G.A. Ross Scholarship Award

Selected Publications

Peer-Reviewed Original Research Articles

1. Safdar A, Rodriguez GH, Mihu CN, Mora-Ramos L, Mulanovich V, Chemaly RF, Champlin RE, Khouri I. Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant 45(2):339-47, 2/2010. PMID: 19561648.
2. de Souza, JA, Saliba, RM, Patah, P, Rondon, G, Ribeiro, R, de Padua Silva, L, Qazilbash, MH, Hosing, C, Popat, U, Efebera, Y, Champlin, RE, and de Lima, M. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1094-9, 9/2009. PMID: 19660722.
3. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-6, 7/2009. PMID: 19539212.
4. de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NT. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant 44(2):81-7, 7/2009. PMID: 19448681.
5. De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi F. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43(11):839-43, 6/2009. PMID: 19151791.
6. Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20(6):1080-5, 6/2009. PMID: 19237479.
7. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718-23, 6/2009. PMID: 19450756.
8. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 6/2009. PMID: 19384931.
9. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899-905, 5/2009. PMID: 19235255.
10. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144-52, 4/2009. PMID: 19168784.
11. Singh H, Najjar AM, Olivares S, Nishii R, Mukhopadhyay U, Alauddin M, Manuri PR, Huls H, Lee DA, Dotti G, Bollard C, Simmons PJ, Shpall EJ, Champlin RE, Gelovani JG, Cooper LJ. PET imaging of T cells derived from umbilical cord blood. Leukemia 23(3):620-2, 3/2009. PMID: 18830258.
12. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9 Suppl 3:S261-5, 2009. PMID: 19778850.
13. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S.. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14(12):1401-7, 12/2008. PMID: 19041063.
14. Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau S, Betancourt D, Li Y, Champlin RE, Andersson BS. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res 32(11):1684-97, 11/2008. PMID: 18339423.
15. Lee SJ, Astigarraga CC, Eapen M, Artz AS, Davies SM, Champlin R, Jagasia M, Kernan NA, Loberiza FR, Bevans M, Soiffer RJ, Joffe S. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant 14(11):1231-8, 11/2008. PMID: 18940677.
16. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112(8):3500-7, 10/2008. PMID: 18664621.
17. Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 112(5):1628-37, 9/1/2008. PMID: 18566326.
18. Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 14(8):859-66, 8/2008. PMID: 18640568.
19. Lee HJ, Gulbis A, De Padua Silva L, Hosing C, Khouri I, de Lima M, Champlin RE, Ciurea SO. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant 42(1):67-9, 7/2008. PMID: 18347568.
20. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 6/2008. PMID: 18564354.
21. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-6, 6/2008. PMID: 18411419.
22. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, De Padua Silva L, Kebriaei P, Alousi A, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 19(6):1166-71, 6/2008. PMID: 18272911.
23. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 14(6):672-84, 6/2008. PMID: 18489993.
24. Anderlini P, Swanston N, Rashid A, Bueso-Ramos C, Macapinlac HA, Champlin RE. Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant 14(4):478-80, 4/2008. PMID: 18342791.
25. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJ. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68(8):2961-71, 4/2008. PMID: 18413766.
26. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 111(4):1767-72, 2/15/2008. PMID: 18057230.
27. Nakayama K, Milbourne A, Schover LR, Champlin RE, Ueno NT. Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nat Clin Pract Oncol 5(2):78-89, 2/2008. PMID: 18235440.
28. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 22(2):258-64, 2/2008. PMID: 17989720.
29. Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, Bredeson CN, Eapen M, Horowitz MM. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 109(10):4582-5, 5/2007. e-Pub 2/2007. PMCID: PMC1885491.
30. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ghosh S, Neumann J, Jsu Y, De Jesus J, Qazilbash M, Champlin R, Couriel DR. Hyper-acute GVHD: risk factors, outcomes and clinical implications. Blood 109(7):2751-8, 4/2007.
31. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39(5):279-83, 3/2007. e-Pub 1/29/2007. PMID: 17262062.
32. Madden T, de Lima M, Thapar N, Ngyuen J, Roberson S, Couriel D, Pierre B, Shpall EJ, Jones RB, Champlin RE, Andersson BA. Pharmacokinetics of a once-daily busulfun as part of pretransplantation preparative regimen: a comparison with an every 6-hour schedule. Biol Blood Marrow Transplant 13:56-64, 2007.
33. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108(4):1421-3, 8/2006. PMID: 16601247.
34. Schmitz N, Eapen M, horowitz MM, Zhang MJ, Klein JP, Rizzo JD, Loberiza FR, Gratwohl A, Champlin RE. Long term outcome of patients transplanted with mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 108(13):4288-90, 2006.
35. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104(3):857-64, 8/2004. PMID: 15073038.
36. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104(3):649-54, 8/2004. PMID: 15069017.

Books (edited and written)

1. Champlin RE, Ippoliti C. Supportive Care Manual for Blood and Marrow Transplantation. Summit: Ne York, 2007.

Last updated: 7/31/2014